MARVELD1 antibody (N-Term)

Catalog No. ABIN500236

This Rabbit Polyclonal antibody specifically detects MARVELD1 in WB and EIA. It exhibits reactivity toward Human, Mouse and Rat.

Quick Overview for MARVELD1 antibody (N-Term) (ABIN500236)

Target: MARVELD1 (MARVEL Domain Containing 1 (MARVELD1))

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This MARVELD1 antibody is un-conjugated

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Product Details anti-MARVELD1 Antibody

Binding Specificity: N-Term

Cross-Reactivity (Details): Species reactivity (tested):Human, mouse, rat

Purification: Peptide affinity chromatography

Immunogen: MARVELD1 antibody was raised against a 16 amino acid peptide from near the amino terminus of human MARVELD1.

Isotype: IgG

Application Details

Application Notes: ELISA. Western blot.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: PBS containing 0.02 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: -20 °C

Storage Comment: Store the antibody (in aliquots) at -20 °C.

Target Details for MARVELD1

Target: MARVELD1 (MARVEL Domain Containing 1 (MARVELD1))

Alternative Name: MARVELD1

Background: MARVELD1, (MARVEL domain-containing 1), is one of the MARVEL (MAL and related proteins for vesicle trafficking and membrane link) domain-containing proteins. It is a nuclear-localized protein that is widely expressed in normal human tissues. While it has been reported to be overexpressed in colon cancer, MARVELD1 protein levels are generally lower in several primary tumors including ovary, breast, kidney, bladder and liver. This lower level of MARVELD1 expression in tumors is thought to be due to a higher methylation status of the MARVELD1 promoter as treatment of MDA-MB-361 with 5-aza-2'-deoxycytidine restores MARVELD1 expression (1,3), suggesting that loss of MARVELD1 expression may contribute to tumorgenicity.Synonyms: MARVEL domain-containing protein 1, MRVLDC1

Gene ID: 83742

UniProt: Q9BSK0